China National Medicines (SHA:600511) recorded a 13% year-over-year rise in attributable profit in the third quarter of 2025 to 543.7 million yuan, a Tuesday filing by parent Sinopharm (HKG:1099) said.
Basic EPS was 0.72 yuan in the three months, with revenue rising 3.6% to 13.7 billion yuan.
For the nine months ended Sept. 30, the drug maker's attributable profit and revenue increased 0.7% and 3.6%, respectively, to 1.49 billion yuan and 39.4 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.